A recent meta-analysis analyzing single agent PD-1/PD-L1 inhibitors and irAEs across different cancer types did not include thromboembolism as a toxicity outcome, with only single patient cases of TE events reported as treatment related deaths [12]. The gene discussed is CD274; the disease is cancer.